March 13, 2019

Michael Richman
Chief Executive Officer
NextCure, Inc.
9000 Virginia Manor Road, Suite 200
Beltsville, MD 20705

       Re: NextCure, Inc.
           Amendment No. 1 to
           Draft Registration Statement on Form S-1
           Submitted March 5, 2019
           CIK No. 0001661059

Dear Mr. Richman:

      We have reviewed your amended draft registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No. 1 to Draft Registration Statement on Form S-1

Overview, page 1

1.     We note your response to comment 1. We note in particular from your
response that you
       are defining "first-in-class" in a temporal sense, as the first one of
its kind, and not as an
       adjective describing the quality of a product candidate or
immunomedicine. If you wish
       to continue to use the "first-in-class" description in this way, then to
avoid investor
       confusion as to the meaning of the phrase, please clearly disclose how
you are defining
       the phrase.
 Michael Richman
NextCure, Inc.
March 13, 2019
Page 2
Research and Development Collaboration with Lilly, page 103

2.       We note your response to comment 9. Please provide an aggregate value,
or narrow range
         of values, for each of the research and development support payments,
the option exercise
         payments, and the milestone payments. In this regard, we note that
proceeds from the
         Lilly Agreement have played an important role in financing your
operations and,
         particularly with respect to the research and development support
payments, appear likely
         to continue to be an important source of funding for your operations.
Aggregating these
         payments does not facilitate an investor's understanding of the
relative magnitude and
         probability of receipt of each payment stream.
Choice of Forum, page 155

3.       We note that your forum selection provision identifies the Court of
Chancery of the State
         of Delaware or, if subject matter jurisdiction of such action is
vested exclusively in the
         federal courts, the United States District Court for the District of
Delaware, as the
         exclusive forum for certain litigation, including any "derivative
action." Please disclose
         whether this provision applies to actions arising under the Securities
Act or Exchange
         Act. If the provision applies to Securities Act claims, please also
state that stockholders
         will not be deemed to have waived the company's compliance with the
federal securities
         laws and the rules and regulations thereunder. In that regard, we note
that Section 22 of
         the Securities Act creates concurrent jurisdiction for federal and
state courts over all suits
         brought to enforce any duty or liability created by the Securities Act
or the rules and
         regulations thereunder. If this provision does not apply to actions
arising under the
         Securities Act or Exchange Act, please also ensure that the exclusive
forum provision in
         the governing documents states this clearly.
        You may contact William Demarest at 202-551-3432 or Yolanda Trotter at
202-551-3472
if you have questions regarding comments on the financial statements and
related matters.
Please contact Donald Field at 202-551-3680 or Dietrich King at 202-551-8071
with any other
questions.



FirstName LastNameMichael Richman                                Sincerely,
Comapany NameNextCure, Inc.
                                                                 Division of
Corporation Finance
March 13, 2019 Page 2                                            Office of
Healthcare & Insurance
FirstName LastName